secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0000950170-24-059496
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet Bio Q1 2024 net loss $28.0M; on track for lupus nephritis trial and ADI-270 IND
--------------------------------------------------------------------------------

- Net loss of $28.0M ($0.35 per share) vs $30.9M ($0.72 per share) in Q1 2023.
- Cash and equivalents $247.6M as of March 31, 2024; expected runway into H2 2026.
- On track to initiate Phase 1 of ADI-001 in lupus nephritis in Q2 2024; data expected Q4 2024 or Q1 2025.
- Preclinical data for ADI-270 presented at ASGCT; IND for renal cell carcinoma planned Q2 2024.
- Enrolling MCL patients in ADI-001 GLEAN study; clinical update with 6-month data expected H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000095017024059496/0000950170-24-059496-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000095017024059496/acet-20240514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-059496

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer